Insider Trading March 16, 2026 10:49 AM

Senseonics Director Purchases $100,275 in Stock Amid Weak Share Performance

Douglas Roeder adds 17,500 shares as company reports mixed Q4 2025 results and faces investor scrutiny

By Avery Klein SENS

Senseonics Holdings director Douglas A. Roeder purchased 17,500 shares of the company's common stock on March 13, 2026, paying $5.73 per share for a total outlay of $100,275. The transaction was disclosed in a Form 4 filing and follows a difficult 12-month period for the stock, which has fallen more than 52% and recently traded near a 52-week low. The company also reported fourth-quarter 2025 results that show strong revenue growth but continued losses and rising operating costs.

Senseonics Director Purchases $100,275 in Stock Amid Weak Share Performance
SENS

Key Points

  • Director Douglas A. Roeder bought 17,500 shares at $5.73 each on March 13, 2026, totaling $100,275; post-transaction direct ownership is 119,731 shares.
  • Senseonics reported Q4 2025 revenue of $14.3 million, a 72% increase year-over-year, but posted an EPS loss of $0.46 and an EBIT loss of $21 million.
  • Analyst reaction includes Stifel maintaining a Hold rating with a $9.00 price target, highlighting concerns about cash burn despite gross margins beating expectations.

Summary: Senseonics Holdings director Douglas A. Roeder bought 17,500 shares of the company's common stock at $5.73 per share on March 13, 2026, for a total of $100,275, according to a Form 4 filing with the Securities and Exchange Commission. The purchase occurred while the stock was trading close to its 52-week low, and follows a year in which shares have fallen by more than half. The company recently released fourth-quarter 2025 results that combined substantial top-line growth with continued net losses and higher operating expenses.

Insider purchase details

The Form 4 filing shows the transaction took place on March 13, 2026. After the acquisition, Roeder directly holds 119,731 shares of Senseonics common stock. The 17,500-share buy was completed at $5.73 per share, bringing the transaction value to $100,275. At the time of the trade the market had the stock trading near a 52-week low of $5.25, reflecting a year-over-year decline in excess of 52 percent.

Market context and valuation note

Public commentary included an InvestingPro assessment referenced in company coverage that labels the shares as appearing undervalued with a reported trading level of $6.26. The InvestingPro material is cited as a resource for deeper valuation analysis and additional research material.

Earnings and analyst reaction

Senseonics disclosed its fourth-quarter 2025 financial results showing revenue of $14.3 million, representing a 72 percent increase from the year-ago quarter. Despite the strong revenue gain, the company reported a loss per share of $0.46. Rising operating expenses contributed to an EBIT loss of $21 million, a shortfall slightly larger than Stifel's estimate of a $19 million EBIT loss. Stifel maintained a Hold rating on the stock and set a price target of $9.00, citing concerns around cash burn. The report noted that gross margins exceeded expectations, even as the aggregate financial results prompted a negative market reaction.

Takeaway

The insider purchase by a company director comes against a backdrop of revenue growth paired with ongoing operating losses and heightened investor scrutiny. The Form 4 disclosure confirms the director-level buy and updated shareholding, while recent quarterly results and an analyst Hold underscore both opportunities and financial challenges the company faces as it manages margins and cash flow.


Note: This article reports facts from the Form 4 disclosure and the companys published fourth-quarter 2025 results and related analyst commentary. It does not offer investment advice.

Risks

  • Continued cash burn and higher operating expenses could pressure the company's financial position and ability to fund operations without additional capital - this impacts investors and the healthcare/medical device sector.
  • Negative market reaction to mixed financial results indicates sensitivity in the stock, which may increase volatility for current and prospective shareholders.
  • The share price has declined more than 52% over the last year and traded near a 52-week low, reflecting persistent market skepticism and valuation risk.

More from Insider Trading

Arcutis Biotherapeutics CEO Executes Stock Sale Amid Mixed Quarterly Financial Results May 6, 2026 Extreme Networks Director Executes $1.14 Million Stock Sale May 6, 2026 Paysign Executive Joan Herman Executes Stock Sale via 10b5-1 Plan May 6, 2026 Rockwell Automation Executive Disposes of Shares Following Option Exercise May 6, 2026 TD SYNNEX Director Richard Hume Executes $1.17 Million Stock Sale via Pre-Planned Trading Program May 6, 2026